Malignant pleural mesothelioma co-opts BCL-XL and autophagy to escape apoptosis
Abstract Escape from programmed cell death is a hallmark of cancer. In this study, we investigated the anti-apoptotic mechanisms and explored the therapeutic potential of BCL-2 homology domain-3 (BH3) mimetics in malignant pleural mesothelioma (MPM), a lethal thoracic malignancy with an extreme dear...
Main Authors: | Duo Xu, Shun-Qing Liang, Zhang Yang, Haitang Yang, Rémy Bruggmann, Simone Oberhaensli, Sabina Berezowska, Thomas M. Marti, Sean R. R. Hall, Patrick Dorn, Gregor J. Kocher, Ralph A. Schmid, Ren-Wang Peng |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-04-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-021-03668-x |
Similar Items
-
Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
by: Surein Arulananda, et al.
Published: (2021-06-01) -
Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma
by: Duo Xu, et al.
Published: (2019-10-01) -
Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma
by: Haitang Yang, et al.
Published: (2020-11-01) -
Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight
by: Duo Xu, et al.
Published: (2020-09-01) -
A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma
by: Surein Arulananda, et al.
Published: (2021-05-01)